Hepatocellular stem cells

Cancer Biomarkers

Volumn 3, Issue 4-5, 2007, Pages 251-262

  Kitisina, K ^a   Shettya, K ^a,b   Mishra, L ^c   Johnsona, L B ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Hepatocellular progenitor stem cells; Oval cell; Regeneration

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ALBUMIN; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN; CCAAT ENHANCER BINDING PROTEIN; CD34 ANTIGEN; CHROMOGRANIN A; CYTOKERATIN 19; CYTOKERATIN 7; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; LIGNAN DERIVATIVE; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; NVP AEW 541; PROTEIN SERINE THREONINE KINASE INHIBITOR; SB 208; SCATTER FACTOR; SEMAXANIB; SOMATOMEDIN; SORAFENIB; SU 11271; SU 11606; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TYRPHOSTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER STEM CELL; CELL ACTIVATION; CELL DIFFERENTIATION; CELL LINEAGE; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG TARGETING; GENE MUTATION; HUMAN; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER DEVELOPMENT; LIVER REGENERATION; LIVER RESECTION; LIVER TRANSPLANTATION; MICROSATELLITE INSTABILITY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; STEM CELL; ANIMAL; CYTOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; HEPATOCYTES; HUMANS; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 38449087864     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/cbm-2007-34-509     Document Type: Article

References (145)

1. G.K. Abou-Alfa et al., Phase II study of sorafenib in patients with advanced hepatocellular carcinoma, J Clin Oncol 24(26) (2006), 4293-4300.
2. M. Abou-Shady et al., Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma, Am J Surg 177(3) (1999), 209-215.
3. P. Akerman et al., Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy, Am J Physiol 263 4 Pt 1) (1992), G579-0585.
4. M.R. Alison and M.J. Lovell, Liver cancer: The told of stem cells, Cell Prolif 38(6) (2005), 407-421.
5. P. Bedossa et al., Transforming growth factor-beta 1 (TGF- beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers, Hepatology 21(3) (1995), 760-766.
6. H.C. Bisgaard et al., Modulation of keratin 14 and alpha-fetoprotein expression during hepatic oval cell proliferation and liver regeneration, J Cell Physiol 159(3) (1994), 475-484.
7. L. Boix et al., c-met mRNA overexpression in human hepatocellular carcinoma, Hepatology 19(1) (1994), 88-91.
8. K. Breuhahn, T. Longerich and P. Schirmacher, Dysregulation of growth factor signaling in human hepatocellular carcinoma, Oncogene 25 27) (2006), 3787-3800.
9. J.S. Campbel et al., Expression of suppressors of cytokine signaling during liver regeneration, J Clin Invest 107(10) (2001), 1285-1292.
10. T. Chiba et al., Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties, Hepatology 44 1 ) (2006), 240-251.
11. J.G. Christensen et al., A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo, Cancer Res 63(21) (2003), 7345-7355.
12. B.D. Cohen et al., Combination therapy enhances the inhibition of tumor growth with the fuUy human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871, Clin Cancer Res 11 5) (2005), 2063-2073.
13. D.E. Cressman et al., Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice, Science 274 5291) (1996), 1379-1383.
14. H.A. Crosby et al., Progenitor cells of the biliary epithelial cell lineage, Semin Cell Dev Biol 13(6) (2002), 397-403.
15. W. Cui et al., TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in ft-msgenic mice, Cell 86(4) (1996), 531-542.
16. A. D'Errico et al., Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: Its specific receptor c-met does, Hepatology 24(1) (1996), 60-64.
17. M.D. Dabeva and D.A. Shafritz, Activation, proliferation, and differentiation of progenitor cells into bepatocytes in the D-galactosamine model of liver regeneration, Am J Pathol 143 6) (1993), 1606-1620.
18. A.T. De Souza et al., Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors, Oncogene 10(9) (1995), 1725-1729.
19. R. De Vos and V. Desmet, Ultrastructural characteristics of novel epithelial cell types identified in human pathologic liver specimens with chronic ductular reaction, Am J Pathol 140(6) (1992), 1441-1450.
20. R. Derynck, R.J. Akhurst and A. Balmain, TGF-beta signaling in tumor suppression and cancer progression, Nat Genet 29(2) (2001), 117-129.
21. V. Desmet, T. Roskams and P. Van Eyken, Ductular reaction in the liver, Pathol Res Pract 191(6) (1995), 513-524.
22. C. Dong et al., Micrombule binding to Smads may regulate TGF beta activity, Mol Cell 5(1) (2000), 27-34.
23. H.A. Dunsford et al., Different lineages of chemically induced hepatocellular carcinoma in rats defined by monoclonal antibodies, Cancer Res 49(17) (1989), 4894-4900.
24. H.A. Dunsford and S. Sell, Production of monoclonal antibodies to preneoplastic liver cell populations induced by chemical carcinogens in rats and to transplantable Morris hepatomas, Cancer Res 49 17) (1989), 4887-4893.
25. E.A. Efimova et al., Effects of human hepatocyte growth factor on the proliferation of human hepatocytes and hepatocellular carcinoma cell lines, Eur Surg Res 36(5) (2004), 300-307.
26. H.B. El-Serag, Hepatocellular carcinoma: Recent trends in the United States, Gastroenterology 127(5 Suppl 1) (2004), S27-S34.
27. H.B. El-Serag and A.C. Mason, Rising incidence of hepatocellular carcinoma in the United States, N Engl J Med 340(10) (1999 , 745-750.
28. N.V. Engelhardt et al., Common antigens of mouse oval and biliary epithelial cells. Expression on newly formed hepatocytes, Differentiation 45(1) (1990), 29-37.
29. R.P. Evarts et al., A precursor-product relationship exists between oval cells and hepatocytes in rat liver, Carcinogenesis 8(11) (1987), 1737-1740.
30. R.P. Evarts et al., In vivo differentiation of rat liver oval cells into hepatocytes, Cancer Res 49(6) (1989), 1541-1547.
31. O. Falkowski et al., Regeneration of hepatocyte 'buds' in cirrhosis from intrabiliary stem cells, J Hepatol 39(3) (2003), 357-364.
32. E. Farber, Similarities in the sequence of early histological changes induced in the liver of the rat by ethionine, 2-acetylamino-fluorene, and 3′-methyl-4-dimethylaminoazobenzene, Cancer Res 16(2) (1956), 142-148.
33. J.L. Farber and R.J. Gerson, Mechanisms of cell injury with hepatotoxic chemicals, Pharmacol Rev 36(2 Suppl) (1984), 71S-75S.
34. N. Fausto, Lessons from genetically engineered animal models. V. Knocking out genes to study liver regeneration: Present and future, Am J Physiol 277(5 Pt 1) (1999), G917-G921.
35. N. Fausto, Liver regeneration and repair: Hepatocytes, progenitor cells, and stem cells, Hepatology 39(6) (2004), 1477-1487.
36. N. Fausto, J.S. Campbell and K.J. Riehle, Liver regeneration, Hepatology 43(2 Suppl 1) (2006), S45-S53.
37. M.J. FitzGerald et al., Rapid DNA binding by nuclear factor kappa B in hepatocytes at the start of liver regeneration, Cell Growth Differ 6(4) (1995), 417-427.
38. R. Gebhardt and G.M. Williams, Glutamine synthetase and hepatocarcinogenesis, Carcinogenesis 16(8) (1995), 1673-1681.
39. M. Golding et al., Oval cell differentiation into hepatocytes in the acetylaminofluorene-treated regenerating rat liver, Hepatology 22(4 Pt 1) (1995), 1243-1253.
40. J. Guirouilh et al., Expression of hepatocyte growth factor in human hepatocellular carcinoma, J Hepatol 34(1) (2001), 78-83.
41. L. Guo et al., Studies of ligand-induced site-specific phosphorylation of epidermal growth factor receptor, J Am Soc Mass Spectrom 14 9) (2003), 1022-1031.
42. T. Hayashi et al., Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment, Clin Cancer Res 10 22) (2004), 7540-7546.
43. G.M. Higgins and R.M. Anderson, Experimental pathology of the liver. I. Restoration of the liver of the white rat following partial surgical removal, Arch Pathol 12 (1931), 186-202.
44. T. Hisaka et al., Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: Relationship to cell proliferation, Int J Oncol 14(3) (1999), 453-460.
45. D.C. Hixson et al., Differentiation status of rat ductal cells and ethionine-induced hepatic carcinomas defined with surface-reactive monoclonal antibodies, Exp Mol Pathol 68(3) (2000), 152-169.
46. M.D. Hjelmeland et al., SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility, Mol Cancer Ther 3(6) (2004), 737-745.
47. E. Houssaint, Differentiation of the mouse hepatic primordium. II. Extrinsic origin of the haemopoietic cell line, Cell Differ 10 5) (1981), 243-252.
48. C.C. Hsia et al., Occurrence of oval-type cells in hepatitis B virus-associated human hepatocarcinogenesis, Hepatology 16 6) (1992), 1327-1333.
49. C.C. Hsia, S.S. Thorgeirsson and E. Tabor, Expression of hepatitis B surface and core antigens and transforming growth factor-alpha in "oval cells" of the liver in patients with hepatocellular carcinoma, J Med Virol 43(3) (1994), 216-221.
50. Y. Inui et al., Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma, Gastroenterology 107(6) (1994), 1799-1804.
51. M. Iwai et al., Increased secretion of tumour necrosis factor and interleukin 6 from isolated, perfused liver of rats after partial hepatectomy, Cytokine 13(1) (2001), 60-64.
52. S. Kang-Park et al., Activation of the IGF-II gene by HBV-X protein requires PKC and p44/p42 map kinase signalings, Biochem Biophys Res Commun 283(2) (2001), 303-307.
53. S. Kanzler et al., Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis, Oncogene 20(36) (2001), 5015-5024.
54. D. Karavias et al., The effect of ischemia on the regeneration of the cholestatic liver. An experimental study, Hepatogastroenterology 49(44) (2002), 456-460.
55. V. Katuri et al., Inactivation of ELF/TGF-beta signaling in human gastrointestinal cancer, Oncogene 24(54) (2005), 8012-8024.
56. A. Kikuchi, Tumor formation by genetic mutations in the components of the Wnt signaling pathway, Cancer Sci 94(3) (2003), 225-229.
57. H.G. Kim et al., Expression of transforming growth factor beta-1 in chronic hepatitis and hepatocellular carcinoma associated with hepatitis C virus infection, Korean J Intern Med 15(3) (2000), 165-170.
58. R. Kinosita, Studies on the carcinogenic chemical substances, Sic Oathol jpn 27 (1937), 665-727.
59. S. Kira et al., Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma, Liver 17(4) (1997), 177-182.
60. L.G. Koniaris et al., Liver regeneration, J Am Coll Surg 197 4) (2003), 634-659.
61. C. Lafarge-Frayssinet et al., Antisense insulin-like growth factor I transferred into a rat hepatoma cell line inhibits tumorigenesis by modulating major histocompatibility complex I cell surface expression, Cancer Gene Ther 4(5) (1997), 276-285.
62. N. Le Douarin and E. Houssaint, Role of the mesoderm in the induction of the synthesis of glycogen during differentiation of the hepatic endoderm, C R Acad Sci Hebd Seances Acad Sci D 264(15) (1967), 1872-1874.
63. S. Lee, U. Park and Y.I. Lee, Hepatitis C virus core protein transactivates insulin-like growth factor II gene transcription through acting concurrently on Egr1 and Sp1 sites, Virology 283(2) (2001), 167-177.
64. Y.I. Lee et al., The human hepatitis B virus transactivator X gene product regulates Sp1 mediated transcription of an insulin-like growth factor II promoter 4, Oncogene 16(18) (1998), 2367-2380.
65. J.M. Lemire, N. Shiojiri and N. Fausto, Oval cell proliferation and the origin of small hepatocytes in liver injury induced by D-galactosamine, Am J Pathol 139(3) (1991), 535-552.
66. L. Libbrecht et al., Deep intralobular extension of human hepatic 'progenitor cells' correlates with parenchymal inflammation in chronic viral hepatitis: Can 'progenitor cells' migrate? J Pathol 192 3) (2000), 373-378.
67. T. Longerich et al., Factors of transforming growth factor beta signaling are co-regulated in human hepatocellular carcinoma, Virchows Arch 445(6) (2004), 589-596.
68. K.N. Lowes et al., Oval cell numbers in human chronic liver diseases are directly related to disease severity, Am J Pathol 154(2) (1999), 537-541.
69. G.A. Macdonald et al., Microsatellite instability and loss of heterozygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis, Hepatology 28(1) (1998), 90-97.
70. G.K. Michalopoulos and M.C. DeFrances, Liver regeneration, Science 276(5309) (1997), 60-66.
71. B. Mishra et al., Loss of cooperative function of transforming growth factor-beta signaling proteins, smad3 with embryonic liver fodrin, a beta-sppctrin, in primary biliary cirrhosis, Liver Int 24(6) (2004), 637-645.
72. L. Mishra et al., Elf3 encodes a novel 200-kD beta-spectrin: Role in liver development, Oncogene 18(2) (1999), 353-364.
73. L. Mishra et al., The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer, Oncogene 24(37) (2005), 5775-5789.
74. C.S. Mitsiades et al., Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors, Cancer Cell 5(3) (2004), 221-230.
75. P. Moinzadeh et al., Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade-results of an explorative. CGH meta-analysis, Br J Cancer 92(5) (2005), 935-941.
76. I. Munoz-Sanjuan and A.H. Brivanlou, Neural induction, the default model and embryonic stem cells, Nat Rev Neurosci 3(4) (2002), 271-280.
77. P. Nagy, H.C. Bisgaard and S.S. Thorgeirsson, Expression of hepatic transcription factors during liver development and oval cell differentiation, J Cell Biol 126(1) (1994), 223-233.
78. T. Nakamura, Growth factor and growth inhibitor for hepatocyte proliferation, Gan To Kagaku Ryoho 16(3 Pt 2) (1989), 481-488.
79. V. Neaud et al., Human hepatic myofibroblasts increase invasiveness of hepatoccellular carrinoma cells: Evidence for a role of hepatocyte growth factor, Hepatology 26(6) (1997), 1458-1466.
80. J.T. Nhieu et al., Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation, Am J Pathol 155(3) (1999), 703-710.
81. Y. Nishikawa, M. Wang and B.I. Carr, Changes in TGF-beta receptors of rat hepatocytes during primary culture and liver regeneration: Increased expression of TGF-beta receptors associated with increased sensitivity to TGF-beta-mediated growth inhibition, J Cell Physiol 176 3) (1998), 612-623.
82. M. Oft, K.H. Heider and H. Beug, TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis, Curr Biol 8(23) (1998), 1243-1252.
83. Y. Oka et al., M6P/IGF2R turnor suppressor gene mutated in hepatocellular carcinomas in Japan, Hepatology 35(5) (2002), 1153-1163.
84. M.M. Oosthuizen, N. Ndaba and J.A. Myburgh, Rat hepato-proliferin revealed the status of a complete hepatomitogen in human hepatoma cells, Transplant Proc 37(1) (2005), 89-92.
85. K. Overturf et al., Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytes, Am J Pathol 151(5) (1997), 1273-1280.
86. K. Overturf et al., Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinacmia type I, Nat Genet 12(3) (1996), 266-273.
87. P.S. Pahlavan et al., Prometheus' challenge: Molecular, cellular and systemic aspects of liver regeneration, J Surg Res 134(2) (2006), 238-251.
88. Y.N. Park et al., Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: Resistance mechanism to transforming growth factor-beta, Hepatogastroenteralogy 51(56) (2004), 396-400.
89. B.E. Petersen et al., Bone marrow as a potential source of hepatic oval cells, Science 284(5417) (1999), 1168-1170.
90. B.E. Petersen et al., Mouse A6-positive hepatic oval cells also express several hematopoietic stem cell markers, Hepatology 37(3) (2003), 632-640.
91. C.S. Potten and M. Loeffler, Stem cells: Attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt, Development 110(4) (1990), 1001-1020.
92. M. Reiss, Transforming growth factor-beta and cancer: A love-hate relationship? Oncol Res 9(9) (1997), 447-457.
93. J.A. Rhim et al., Replacement of diseased mouse liver by hepatic cell transplantation, Science 263(5150) (1994), 1149-1152.
94. L.R. Roberts and G.J. Gores, Hepatocellular carcinoma: Molecular pathways and new therapeutic targets, Semin Liver Dis 25(2) (2005), 212-225.
95. T. Roskams, Different types of liver progenitor cells and their niches, J Hepatol 45(1) (2006), 1-4.
96. T. Roskams, Liver stem cells and their implication in hepato-cellular and cholangiocarcinoma, Oncogene 25(27) (2006), 3818-3822.
97. T. Roskams et al., Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease, Am J Pathol 163(4) (2003), 1301-1311.
98. T.A. Roskams, L. Libbrecht and V.J. Desmet, Progenitor cells in diseased human liver, Semin Liver Dis 23(4) (2003), 385-396.
99. T.A. Roskams et al., Nomenclature of the finer branches of the biliary tree: Canals, ductules, and ductular reactions in human livers, Hepatology 39(6) (2004), 1739-1745.
100. A. Ryo et al., Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC, Nat Cell Biol 3(9) (2001), 793-801.
101. D. Sachdev et al., A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I, Cancer Res 63(3) (2003), 627-635.
102. E.P. Sandgren et al., Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene, Cell 66 2) (1991), 245-256.
103. L.P. Sanford et al., TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes, Development 124(13) (1997), 2659-2670.
104. C. Sarraf et al., Cell behavior in the acetylaminofluorene-treated regenerating rat liver. Light and electron microscopic observations, Am J Pathol 145(5) (1994), 1114-1126.
105. S. Satoh et al., AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1, Nat Genet 24(3) (2000), 245 250.
106. A.F. Schier and W.S. Talbot, Nodal signaliag and the zebrafish organizer, Int J Dev Biol 45(1) (2001), 289-297.
107. K. Scotlandi et al., Blockage of insulin-like growth factor-I receptor inhibits the growth cf Ewing's sarcoma in athymic mice, Cancer Res 58(18) (1998), 4127-4131.
108. K. Scotlandi et al., Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors, Cancer Res 65(9) (2005), 3868-3876.
109. S. Sell, Heterogeneity and plasticity of hepatocyte lineage cells, Hepatology 33(3) (2001), 738-750.
110. S. Sell, K. Osborn and H.L. Leffert, Autoradiography of "oval cells" appearing rapidly in the livers of rats fed N-2-fluorenylacetamide in a choline, devoid diet, Carcinogenesis 2(1) (1981), 7-14.
111. K.D. Shah and M.A. Gerber, Development of intrahepatic bile ducts in humans. Immunohistochemical study using monoclcnal cytokeratin antibodies, Arch Pathol Lab Wed 113(10) (1989), 1135-1138.
112. H. Shinozuka et al., Effects of a choline-devoid diet on the emergence of gamma-glutamyltranspeptidase-positive foci in the liver of carcinogen-treated rats, Cancer Res 39(7 Pt 1) (1979), 2515-2521.
113. A.E. Sirica and H.P. Cihla, Isolation and partial characterizations of oval and hyperplastic bile ductular cell-enriched populations from the livers of carcinogen and noncarcinogen-treated rats, Cancer Res 44(8) (1984), 3454-3466.
114. D.B. Solt, A. Medline and E. Farber, Rapid emergence of carcinogen-induced hyperplastic lesions in a new model for the sequential analysis of liver carcinogenesis, Am J Pathol 88 3) (1977), 595-618.
115. M.B. Sporn and A.B. Roberts, Transforming growth factor-beta: New chemical forms and new biological roles, Biofactors 1(1) (1988), 89-93.
116. J.W. Steiner, Z.M. Perz and L.B. Taichman, Cell population dynamics in the liver. A review of quantitative morphological techniques applied to the study of physiological and pathological growth, Exp Mol Pathol 5(2) (1966), 146-181.
117. R.E. Stowell and C.S. Lee, Histochemical studies of mouse liver after single feeding of carbon tetrachloride, AMA Arch Pathol 50 5) (1950), 519-537.
118. K.A. Stuart et al., Hepatocyte growth factor/scatter factor-induced intracellular signalling, Int J Exp Pathol 81(1) (2000), 17-30.
119. S.R. Sue et al., Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcirnoma, Ann Surg 222(2) (1995), 171-178.
120. Y. Tang et al., Disruption of transforming growth factor-beta signaling in ELF beta-spectrin-deficient mice, Science 299(5606) (2003), 574-577.
121. Y. Tang et al., Transforming growth factor-beta suppresses nonmetastatic, colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis, Cancer Res 65(10) (2005), 4228-4237.
122. K. Taniguchi et al., Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas, Oncogene 21(31) (2002), 4863-4871.
123. R. Taub, Liver regeneration: From myth to mechanism, Nat Rev Mol Cell Biol 5(10) (2004), 836-847.
124. D. Tavian et al., u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma, Int J Cancer 87(5) (2000), 644-649.
125. L.B. Tee et al., Dual phenotypic expression of hepatocytes and bile ductular markers in developing and preneoplastic rat liver, Carcinogenesis 17(2) (1996), 251-259.
126. N.D. Theise et al., The canals of Hering and hepatic stem cells in humans, Hepatology 30(6) (1999), 1425-1433.
127. D. Tosh and A. Strain, Liver stem cells - prospects for clinical use, J Hepatol 42(Suppl 1) (2005), S75-S84.
128. C. Trautwein et al., Acute-phase response factor, increased binding, and target gene transcription during liver regenera tion, Gastroenterology 110(6) (1996), 1854-1862.
129. J.F. Tsai et al., Clinical relevance of transforming growth factor-beta 1 in the urine of patients with hepatocellular carcinoma, Medicine (Baltimore) 76(3) (1997), 213-226.
130. T. Tsukazaki et al., SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor, Cell 95(6) (1998), 779-791.
131. T. Uenishi et al., Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence, Cancer Sci 94(10) (2003), 851-857.
132. D. van der Kooy and S. Weiss, Why stem cells? Science 287 5457) (2000), 1439-1441.
133. P. Van Eyken et al., The development of the intrahepatic bile ducts in man: A keratin-immunohistochemical study, Hepatology 8(6) (1988), 1586-1595.
134. P. Van Eyken, R. Sciot and V. Desmet, Intrahepatic bile duct development in the rat: A cytokeratin-immunohistochemical study, Lab Invest 59(1) (1988), 52-59.
135. P. Van Eyken et al., Cytokeratin expression in hepatocellular carcinoma: an immunohistochemical study, Hum Pathol 19(5) (1988), 562-568.
136. C.J. Vessey and P.M. de la Hall, Hepatic stem cells: A review, Pathology 33(2) (2001), 130-141.
137. K.E. Wack et al., Sinusoidal ultrastructure evaluated during the revascularization of regenerating rat liver, Hepatology 33 2) (2001), 363-378.
138. A. Wodarz and R. Nusse, Mechanisms of Wnt signaling in development, Annu Rev Cell Dev Biol 14 (1998), 59-88.
139. P.C. Wu et al., Hepatocellular carcinoma expressing both hepatocellular and biliary markers also expresses cytokeratin 14, a marker of bipotential progenitor cells, J Hepatol 31(5) (1999), 965-966.
140. M.C. Yakicier et al., Smad2 and Smad4 gene mutations in hepatocellular carcinoma, Oncogene 18(34) (1999), 4879-4883.
141. H. Yakushiji et al., DNA mismatch repair deficiency in curatively resected sextuple primary cancers in different organs: A molecular case report, Cancer Lett 142(1) (1999), 17-22.
142. Y. Yamada et al., initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor, Proc Natl Acad Sci USA 94(4) (1997), 1441-1446.
143. H. Yamamoto et al., Infrequent widespread microsatellite instability in hepatocellular carcinomas, Int J Oncol 16(3) (2000), 543-547.
144. T.O. Yau et al., HDPRI, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing, Oncogene 24 9) (2005), 1607-1614.
145. J. Zhang et al., Expression of transforming growth factor-alpha and hepatitis B surface antigen in human hepatocellular carcinoma tissues and its significance, World J Gastroenterol 10(6) (2004), 830-833.